EFTA02572473

From: Steven Sinofsky < I=> Sent: Thursday, November 2, 2017 10:24 PM To: Masha Drokova Cc: Jeffrey E. Subject: Re: Greetings Masha, =br> I apologize for the delay. I was at some events in in U= where I did not have connectivity. I have worked o= a related portfolio company so I will have to be a bit abstract on the spe=ifics of this opportunity. So please excuse these brief thoughts. Als=, the only information I had was what was provided in your mail which was l=mited relative to any detailed analysis. * In gene=al the challenge with glucose measurement is the finger prick. Any device t=at relies on this will only be marginally better than any other device, whe=her or not there is software or a slightly more convenient measuring device= This is a statement about the inconvenience of a prick (and long term chal=enges) but also the medical challenges on relying on that point in time. * My sense is that going down the path of an innovation, that still h=s a prick, but requires a level of FDA approval is a difficult one to appro=ch. * This is a very crowded space. There are a lot of apps, a lo= of measuring devices, a lot of mixtures of app and measuring devices. It i= very difficult to avoid appearing as a commodity to consumers. *=While I understand there is potential to see innovation using novel approac=es to analysis of data, it is not clear to me how much better the approach c=n be for an individual with data. * The real opportunity I might s=e is around measuring glucose or some related telemetry to assist in compli=nce that is outside the scope of a finger prick and measuring glucose direc=ly. It seems like we should have some other data point upon which to apply m=chine learning. I hope this helps...any friend of Jr. is a friend of mine. On Nov 1, 2017, at 4:43 PM, Masha Droko=• &=t; wrote: Thank yo= Jeffrey. Steve, great meeting you. Would appreciate your f=edback On Nov 1, 2017, at 9:31 AM, jeffrey E. <[email protected]> wrote: =br> steve can you give=some guidance target="_b On Wed Nov 1 2017 at 12:20 PM, Masha Drokova rote: EFTA_R1_01742096 EFTA02572473 I'm l=oking to invest at the company doing AI-based glucose monitoring system for=people with diabetes. We made tech evaluation, talked to a few expert= and more a question about the market and regulations. likely no, bec=use it's complex area, but still thinking of them. <=pan style="background-color:rgba(255,255,255,0)"> May be someone in your ne=work who knows this area and can advise on this kind of tech? <=div> Center Health Deck: https://drive.google.com/file/d/095O93D3IJArEbnisdll4elVob0U/view <=pan>Center Health is building a= Al-based glucose monitoring system for the 1 in 11 Americans who suff=r from diabetes, based on machine learning and their personalized Al, =ria. Users subscribe to their disposable test strips, a $14B/yr US market, w=ich are delivered monthly, as Aria learns about their diabetes and prompts b=havioral changes to lower blood sugar. The system is an order of m=gnitude cheaper than existing technologies, premised on leveraging data to h=lp users see what daily elements are affecting their blood sugar, and p=edicting dangerous highs and lows before they happen. </=iv> Pros — Existing glucometers from big companies=are very old-fashioned and outdated, those companies make their revenue fro= overpriced strips — Direct competitors, such as =/span>iHealth and Dario have negative customer reviews and minor —&=bsp;Uses FDA-approved circuits to get the approval in an automated manner</=ont> =i>Cons — Enormous pr=ssure both from the industry players and companies such as Apple and Google=that try to develop non-invasive glucose monitoring that will wipe out test=strip products <=ont face="Roboto-Regular">— Hardware startup without a product to=sell yet, finalizing the development — Young team = please not= The information contained in this communication is confidential= may be attorney-client privileged, may constitute inside information, a=d is intended only for the use of the addressee. It is the property of.IEE Unauthorized use, disclosure or copying of this communication or=any part thereof is strictly prohibited and may be unlawful. If you have=received this communication in error, please notify us immediately by [email protected] <mailto:[email protected]> , and destroy this communication a=d all copies thereof, 2 EFTA_R1_01742097 EFTA02572474 including all attachments. copyright -all rights r=served 3 EFTA_R1_01742098 EFTA02572475